 Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33 response rate with 2 complete responses across all tumor types harboring NRG1 fusions, and a 36 response rate in patients with NSCLC; ongoing durations of response range from 1.4 11.5 months Seribantumab has been well-tolerated in patients with tumors harboring NRG1 fusions Company to host an investor conference call to discuss these initial results from the CRESTONE study today at 6:00pm ET NEW YORK , May 26, 2022 PRNewswire -- Elevation Oncology, Inc. Nasdaq: ELEV, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced positive initial clinical proof-of-concept data from its ongoing Phase 2 CRESTONE study evaluating the safety and efficacy of seribantumab in patients with advanced solid tumors that harbor NRG1 gene fusions. These data will be presented at the 2022 American Society of Clinical Oncology ASCO Annual Meeting, being held in Chicago from June 3-7, 2022. 